INMB
Price:
$1.24
Market Cap:
$32.97M
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancie...[Read more]
Industry
Biotechnology
IPO Date
2019-02-04
Stock Exchange
NASDAQ
Ticker
INMB
According to INmune Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.76. This represents a change of -49.62% compared to the average of -1.51 of the last 4 quarters.
The mean historical PE Ratio of INmune Bio, Inc. over the last ten years is -30.67. The current -0.76 PE Ratio has changed 147.80% with respect to the historical average. Over the past ten years (40 quarters), INMB's PE Ratio was at its highest in in the March 2017 quarter at 341.04. The PE Ratio was at its lowest in in the September 2016 quarter at -184.29.
Average
-30.67
Median
-6.98
Minimum
-147.35
Maximum
-0.90
Discovering the peaks and valleys of INmune Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 119.87%
Maximum Annual PE Ratio = -0.90
Minimum Annual Increase = -93.32%
Minimum Annual PE Ratio = -147.35
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -0.90 | -59.20% |
| 2024 | -2.21 | -67.20% |
| 2023 | -6.75 | 62.06% |
| 2022 | -4.16 | -23.23% |
| 2021 | -5.42 | -68.22% |
| 2020 | -17.06 | 119.87% |
| 2019 | -7.76 | 7.69% |
| 2018 | -7.21 | -93.32% |
| 2017 | -107.87 | -26.79% |
| 2016 | -147.35 | -81.98% |
The current PE Ratio of INmune Bio, Inc. (INMB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.29
5-year avg
-3.89
10-year avg
-30.67
INmune Bio, Inc.’s PE Ratio is less than CEL-SCI Corporation (-0.39), less than Barinthus Biotherapeutics plc (-0.52), less than Aligos Therapeutics, Inc. (-0.61), less than Tempest Therapeutics, Inc. (-0.32), greater than OnKure Therapeutics, Inc. (-0.98), greater than Mersana Therapeutics, Inc. (-2.07), less than Skye Bioscience, Inc. (-0.54), greater than X4 Pharmaceuticals, Inc. (-5.07), greater than PDS Biotechnology Corporation (-1.75), less than FibroGen, Inc. (0.18),
| Company | PE Ratio | Market cap |
|---|---|---|
| -0.39 | $7.42M | |
| -0.52 | $27.41M | |
| -0.61 | $32.67M | |
| -0.32 | $5.60M | |
| -0.98 | $57.43M | |
| -2.07 | $145.36M | |
| -0.54 | $27.67M | |
| -5.07 | $377.28M | |
| -1.75 | $58.61M | |
| 0.18 | $36.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like INmune Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like INmune Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is INmune Bio, Inc.'s PE Ratio?
How is the PE Ratio calculated for INmune Bio, Inc. (INMB)?
What is the highest PE Ratio for INmune Bio, Inc. (INMB)?
What is the 3-year average PE Ratio for INmune Bio, Inc. (INMB)?
What is the 5-year average PE Ratio for INmune Bio, Inc. (INMB)?
How does the current PE Ratio for INmune Bio, Inc. (INMB) compare to its historical average?